norepinephrine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
sympathomimetic, phenethyl derivatives	1960	51-41-2

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: norepinephrine (R)-Norepinephrine arterenol levarterenol noradrenaline norepinephrine bitartrate (-)-noradrenaline	Precursor of epinephrine that is secreted by the ADRENAL MEDULLA and is a widespread central and autonomic neurotransmitter. Norepinephrine is the principal transmitter of most postganglionic sympathetic fibers, and of the diffuse projection system in the brain that arises from the LOCUS CERULEUS. It is also found in plants and is used pharmacologically as a sympathomimetic. Molecular weight: 169.18 Formula: C8H11NO3 CLOGP: -0.99 LIPINSKI: 0 HAC: 4 HDO: 4 TPSA: 86.71 ALOGS: -1.13 ROTB: 2 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

norepinephrine
(R)-Norepinephrine
arterenol
levarterenol
noradrenaline
norepinephrine bitartrate
(-)-noradrenaline

Precursor of epinephrine that is secreted by the ADRENAL MEDULLA and is a widespread central and autonomic neurotransmitter. Norepinephrine is the principal transmitter of most postganglionic sympathetic fibers, and of the diffuse projection system in the brain that arises from the LOCUS CERULEUS. It is also found in plants and is used pharmacologically as a sympathomimetic.

Molecular weight: 169.18
Formula: C8H11NO3
CLOGP: -0.99
LIPINSKI: 0
HAC: 4
HDO: 4
TPSA: 86.71
ALOGS: -1.13
ROTB: 2

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
6	mg	P

ADMET properties:

Property	Value	Reference
BA (Bioavailability)	3 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
S (Water solubility)	849 mg/mL	Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Bocci G, Oprea TI, Benet LZ

Approvals:

Date	Agency	Company	Orphan
July 13, 1950	FDA	HOSPIRA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Multiple organ dysfunction syndrome	414.66	27.21	226	15687	56526	63416583
Drug ineffective	321.85	27.21	762	15151	1044003	62429106
Cardiac arrest	301.61	27.21	221	15692	92324	63380785
Septic shock	299.47	27.21	194	15719	66435	63406674
Metabolic acidosis	273.45	27.21	159	15754	44910	63428199
Shock	245.17	27.21	119	15794	23344	63449765
Myoglobin urine present	239.15	27.21	52	15861	720	63472389
Hypotension	204.97	27.21	294	15619	272310	63200799
Stress cardiomyopathy	197.11	27.21	78	15835	9372	63463737
Intentional overdose	195.07	27.21	156	15757	73996	63399113
Cardiogenic shock	190.48	27.21	92	15821	17840	63455269
Acute kidney injury	180.47	27.21	272	15641	263143	63209966
Peripheral ischaemia	171.04	27.21	59	15854	4819	63468290
Fatigue	165.81	27.21	16	15897	888012	62585097
Toxic encephalopathy	153.82	27.21	59	15854	6520	63466589
Respiratory failure	145.21	27.21	152	15761	101706	63371403
Acute respiratory distress syndrome	145.20	27.21	84	15829	23450	63449659
Serotonin syndrome	139.82	27.21	88	15825	28594	63444515
Lactic acidosis	139.55	27.21	98	15815	38189	63434920
Renal failure	138.92	27.21	159	15754	117493	63355616
Amylase increased	138.03	27.21	54	15859	6291	63466818
Bradycardia	137.39	27.21	127	15786	73100	63400009
Haemodynamic instability	131.51	27.21	58	15855	9132	63463977
Troponin increased	129.29	27.21	59	15854	10062	63463047
Electrocardiogram QRS complex prolonged	123.77	27.21	49	15864	5889	63467220
Renal injury	111.13	27.21	52	15861	9387	63463722
Toxicity to various agents	106.51	27.21	208	15705	247042	63226067
Pulseless electrical activity	106.11	27.21	47	15866	7474	63465635
Ventricular tachycardia	104.19	27.21	64	15849	19915	63453194
Hyperlactacidaemia	101.98	27.21	35	15878	2814	63470295
Arthralgia	99.17	27.21	13	15900	569697	62903412
Circulatory collapse	96.24	27.21	63	15850	21875	63451234
Headache	95.84	27.21	21	15892	633220	62839889
Dry gangrene	95.64	27.21	24	15889	636	63472473
Blood lactate dehydrogenase increased	93.24	27.21	63	15850	23053	63450056
Nausea	92.29	27.21	50	15863	854421	62618688
Extremity necrosis	91.09	27.21	28	15885	1585	63471524
Pharyngeal haemorrhage	88.89	27.21	22	15891	550	63472559
Ventricular hypokinesia	88.74	27.21	36	15877	4608	63468501
Pulmonary oedema	87.40	27.21	87	15826	54786	63418323
Propofol infusion syndrome	86.16	27.21	24	15889	959	63472150
Acidosis	85.38	27.21	46	15867	11187	63461922
Tachycardia	84.91	27.21	125	15788	118031	63355078
Blood creatine phosphokinase increased	84.16	27.21	66	15847	30364	63442745
Sepsis	82.50	27.21	142	15771	152981	63320128
Blood potassium increased	81.33	27.21	53	15860	18256	63454853
Disseminated intravascular coagulation	77.01	27.21	52	15861	18999	63454110
Drug ineffective for unapproved indication	75.58	27.21	65	15848	33998	63439111
Renal impairment	73.09	27.21	100	15813	88255	63384854
Overdose	71.74	27.21	114	15799	114964	63358145
Electrocardiogram QT prolonged	71.09	27.21	81	15832	59449	63413660
Alanine aminotransferase increased	70.56	27.21	107	15806	103663	63369446
Atrioventricular block first degree	70.28	27.21	35	15878	7238	63465871
Ventricular fibrillation	69.59	27.21	41	15872	11826	63461283
Coagulopathy	68.87	27.21	50	15863	20494	63452615
Pruritus	68.53	27.21	6	15907	361447	63111662
Alopecia	65.66	27.21	5	15908	337531	63135578
Drug intolerance	64.79	27.21	3	15910	308658	63164451
Fear	63.64	27.21	43	15870	15723	63457386
Systolic dysfunction	62.55	27.21	21	15892	1578	63471531
Abdominal discomfort	61.72	27.21	5	15908	320880	63152229
Electrocardiogram ST segment elevation	60.13	27.21	26	15887	3901	63469208
Rash	60.12	27.21	33	15880	560838	62912271
Fall	59.26	27.21	13	15900	392321	63080788
Patent ductus arteriosus	58.15	27.21	26	15887	4224	63468885
Coma	58.04	27.21	76	15837	64288	63408821
Hypoxia	57.68	27.21	73	15840	59719	63413390
Premature delivery	57.66	27.21	53	15860	30228	63442881
Anuria	54.93	27.21	36	15877	12515	63460594
Diabetes insipidus	52.40	27.21	21	15892	2604	63470505
Hyperkalaemia	52.00	27.21	66	15847	54137	63418972
Drug hypersensitivity	51.82	27.21	8	15905	310679	63162430
Nasopharyngitis	51.68	27.21	3	15910	254254	63218855
Pain in extremity	50.01	27.21	11	15902	331475	63141634
Cardio-respiratory arrest	49.77	27.21	68	15845	59891	63413218
Dizziness	49.46	27.21	23	15890	429902	63043207
Left ventricle outflow tract obstruction	49.11	27.21	12	15901	284	63472825
Cardiotoxicity	49.07	27.21	29	15884	8409	63464700
Wrong product administered	49.06	27.21	26	15887	6115	63466994
Reversible cerebral vasoconstriction syndrome	48.72	27.21	20	15893	2638	63470471
Ventricular arrhythmia	47.89	27.21	22	15891	3806	63469303
Hypersensitivity	47.77	27.21	8	15905	292677	63180432
Weight increased	47.63	27.21	5	15908	260787	63212322
Respiratory depression	47.38	27.21	34	15879	13681	63459428
Electrocardiogram ST segment depression	47.19	27.21	20	15893	2857	63470252
Infusion related reaction	46.71	27.21	4	15909	245517	63227592
Cardiomyopathy	46.16	27.21	37	15876	17547	63455562
Vasoplegia syndrome	46.11	27.21	17	15896	1682	63471427
Diarrhoea	45.76	27.21	68	15845	715298	62757811
Acid base balance abnormal	45.11	27.21	11	15902	258	63472851
Anhedonia	44.46	27.21	30	15883	10944	63462165
Weight decreased	44.22	27.21	8	15905	276790	63196319
Swelling	43.90	27.21	8	15905	275370	63197739
Pain	43.05	27.21	75	15838	740553	62732556
Constipation	41.88	27.21	4	15909	224939	63248170
Distributive shock	41.87	27.21	15	15898	1368	63471741
Acute generalised exanthematous pustulosis	41.78	27.21	29	15884	11070	63462039
Back pain	41.41	27.21	8	15905	264137	63208972
Anion gap increased	40.86	27.21	16	15897	1866	63471243
Brain death	40.79	27.21	19	15894	3391	63469718
Off label use	40.52	27.21	298	15615	674164	62798945
Leukocytosis	39.22	27.21	40	15873	25895	63447214
Premature baby	38.90	27.21	36	15877	20699	63452410
Unmasking of previously unidentified disease	38.90	27.21	13	15900	963	63472146
Suicide attempt	38.82	27.21	61	15852	60857	63412252
Malaise	38.33	27.21	29	15884	415925	63057184
Contraindicated product administered	37.68	27.21	5	15908	217643	63255466
Mydriasis	37.59	27.21	28	15885	11928	63461181
Drug interaction	37.15	27.21	134	15779	228997	63244112
Therapeutic product effect decreased	37.14	27.21	3	15910	193184	63279925
Thrombocytopenia	36.05	27.21	101	15812	151056	63322053
Diabetic macroangiopathy	35.88	27.21	8	15905	125	63472984
Unevaluable event	34.91	27.21	53	15860	51333	63421776
Insomnia	34.85	27.21	6	15907	215246	63257863
Sinus bradycardia	34.80	27.21	29	15884	14522	63458587
Oliguria	34.78	27.21	24	15889	9077	63464032
Blood pressure decreased	34.56	27.21	60	15853	64962	63408147
Renal tubular necrosis	33.34	27.21	26	15887	11852	63461257
Activated partial thromboplastin time prolonged	33.19	27.21	21	15892	6872	63466237
Pulmonary hypertensive crisis	32.92	27.21	9	15904	335	63472774
Peripheral swelling	32.50	27.21	13	15900	265929	63207180
Foetal exposure during pregnancy	32.37	27.21	40	15873	31922	63441187
Ischaemic hepatitis	32.36	27.21	14	15899	2102	63471007
Encephalopathy	32.34	27.21	44	15869	38576	63434533
Gait disturbance	32.21	27.21	4	15909	183174	63289935
Vitamin B1 decreased	32.17	27.21	8	15905	204	63472905
Intestinal ischaemia	31.65	27.21	21	15892	7447	63465662
Electrocardiogram repolarisation abnormality	31.45	27.21	12	15901	1305	63471804
Systemic lupus erythematosus	31.34	27.21	7	15906	208911	63264198
Compartment syndrome	31.33	27.21	14	15899	2270	63470839
Brain oedema	31.30	27.21	27	15886	14168	63458941
Bronchopulmonary dysplasia	30.87	27.21	9	15904	424	63472685
Torsade de pointes	30.67	27.21	26	15887	13325	63459784
Acute lung injury	29.40	27.21	12	15901	1559	63471550
Dyspnoea	29.20	27.21	78	15835	661235	62811874
Myocardial stunning	28.63	27.21	7	15906	166	63472943
Neurodevelopmental disorder	28.32	27.21	7	15906	174	63472935
Injury	28.29	27.21	59	15854	73188	63399921
Hypothermia	28.27	27.21	25	15888	13556	63459553
Local anaesthetic systemic toxicity	28.16	27.21	10	15903	889	63472220
Vasoconstriction	28.04	27.21	9	15904	587	63472522
Human herpesvirus 6 infection reactivation	27.67	27.21	8	15905	366	63472743
Depressed level of consciousness	27.56	27.21	53	15860	62025	63411084
Ventricular extrasystoles	27.34	27.21	23	15890	11664	63461445
Heparin-induced thrombocytopenia	27.30	27.21	16	15897	4566	63468543

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Multiple organ dysfunction syndrome	609.23	21.16	427	18745	76139	34861620
Drug ineffective	531.32	21.16	914	18258	455837	34481922
Cardiogenic shock	450.68	21.16	241	18931	26377	34911382
Appendicolith	370.72	21.16	149	19023	8452	34929307
Appendicitis	299.00	21.16	151	19021	14656	34923103
Ventricular fibrillation	229.80	21.16	148	19024	22806	34914953
Septic shock	205.59	21.16	224	18948	71610	34866149
Sepsis	190.60	21.16	333	18839	166228	34771531
Ascites	170.76	21.16	166	19006	46405	34891354
Off label use	163.00	21.16	551	18621	418973	34518786
Hypotension	157.21	21.16	363	18809	221286	34716473
Propofol infusion syndrome	155.47	21.16	45	19127	921	34936838
Cardiac arrest	154.94	21.16	225	18947	95934	34841825
Blood phosphorus increased	153.62	21.16	78	19094	7643	34930116
Shock	138.35	21.16	111	19061	24068	34913691
Abdominal distension	134.49	21.16	163	19009	58329	34879430
Acute kidney injury	130.99	21.16	415	18757	304573	34633186
Fatigue	122.59	21.16	27	19145	370626	34567133
Fear	120.99	21.16	74	19098	10402	34927357
Toxic epidermal necrolysis	120.93	21.16	98	19074	21548	34916211
Respiratory failure	113.55	21.16	209	18963	108363	34829396
Hyponatraemia	107.10	21.16	175	18997	82516	34855243
Rhabdomyolysis	101.76	21.16	154	19018	68009	34869750
Metabolic acidosis	99.17	21.16	121	19051	43559	34894200
Diarrhoea	94.86	21.16	48	19124	389864	34547895
Renal injury	94.60	21.16	65	19107	11130	34926629
Injury	93.65	21.16	83	19089	20604	34917155
Coma	93.27	21.16	120	19052	45558	34892201
Stress	89.03	21.16	96	19076	30251	34907508
Renal failure	85.90	21.16	208	18964	130349	34807410
Anhedonia	83.56	21.16	52	19120	7533	34930226
Weight decreased	83.50	21.16	3	19169	176298	34761461
Lactic acidosis	81.64	21.16	98	19074	34674	34903085
Bradycardia	81.06	21.16	147	19025	75271	34862488
General physical health deterioration	80.82	21.16	201	18971	128068	34809691
Haemodynamic instability	79.77	21.16	55	19117	9468	34928291
Headache	78.77	21.16	9	19163	200626	34737133
Acute respiratory distress syndrome	77.66	21.16	83	19089	25886	34911873
Asthenia	76.73	21.16	20	19152	245231	34692528
Emotional distress	75.51	21.16	64	19108	14962	34922797
Arthralgia	73.83	21.16	5	19167	170036	34767723
Dizziness	69.92	21.16	17	19155	218504	34719255
Vasoplegia syndrome	69.18	21.16	29	19143	1827	34935932
Fall	68.50	21.16	14	19158	202871	34734888
Myasthenia gravis	65.10	21.16	43	19129	6897	34930862
Electrocardiogram QRS complex prolonged	62.79	21.16	37	19135	4857	34932902
Drug reaction with eosinophilia and systemic symptoms	58.57	21.16	81	19091	32931	34904828
Pain in extremity	57.08	21.16	3	19169	126510	34811249
Intestinal ischaemia	56.01	21.16	41	19131	7753	34930006
Dry gangrene	55.62	21.16	17	19155	422	34937337
Anion gap	55.27	21.16	20	19152	847	34936912
Unevaluable event	54.89	21.16	78	19094	32512	34905247
Drug ineffective for unapproved indication	54.28	21.16	66	19106	23649	34914110
Stress cardiomyopathy	53.58	21.16	25	19147	2034	34935725
Myocardial calcification	51.50	21.16	10	19162	29	34937730
Decreased appetite	51.17	21.16	14	19158	166378	34771381
Product dose omission issue	50.56	21.16	4	19168	119707	34818052
Dry mouth	50.51	21.16	72	19100	30093	34907666
Blood uric acid increased	50.43	21.16	42	19130	9582	34928177
Condition aggravated	49.87	21.16	223	18949	191973	34745786
Back pain	48.93	21.16	5	19167	121784	34815975
Rash	48.87	21.16	31	19141	222721	34715038
Peripheral ischaemia	47.99	21.16	33	19139	5654	34932105
Pruritus	47.47	21.16	10	19162	141971	34795788
Compartment syndrome	47.28	21.16	26	19146	2992	34934767
Malaise	46.35	21.16	22	19150	185803	34751956
Burkholderia test positive	45.00	21.16	18	19154	1005	34936754
Hyperdynamic left ventricle	44.82	21.16	12	19160	182	34937577
Acidosis	43.81	21.16	41	19131	10904	34926855
Hyperphosphataemia	42.85	21.16	28	19144	4409	34933350
Pharyngeal haemorrhage	42.64	21.16	16	19156	751	34937008
Electrocardiogram QT prolonged	41.65	21.16	78	19094	40874	34896885
Weight increased	39.58	21.16	3	19169	93030	34844729
Heparin-induced thrombocytopenia	39.22	21.16	29	19143	5566	34932193
Hypertransaminasaemia	36.94	21.16	28	19144	5578	34932181
Pulseless electrical activity	36.80	21.16	31	19141	7180	34930579
Drug therapy	36.49	21.16	16	19156	1125	34936634
Cholestasis	36.13	21.16	58	19114	26890	34910869
Dyspnoea	35.84	21.16	98	19074	376684	34561075
Constipation	35.52	21.16	159	19013	136823	34800936
Gait disturbance	35.51	21.16	3	19169	85137	34852622
Renal impairment	35.25	21.16	123	19049	94390	34843369
Abdominal pain	35.25	21.16	180	18992	163438	34774321
Analgesic therapy	35.21	21.16	15	19157	983	34936776
Diabetes insipidus	34.60	21.16	21	19151	2907	34934852
Coagulopathy	34.25	21.16	48	19124	19741	34918018
Cough	34.14	21.16	20	19152	150120	34787639
Insomnia	33.34	21.16	8	19164	103899	34833860
Dehydration	32.99	21.16	15	19157	129954	34807805
Respiratory depression	32.06	21.16	42	19130	16203	34921556
Pulse absent	31.81	21.16	26	19146	5777	34931982
Sleep disorder therapy	31.60	21.16	14	19158	1009	34936750
Chest pain	31.60	21.16	15	19157	126747	34811012
Overdose	30.97	21.16	115	19057	90944	34846815
Incorrect route of product administration	30.26	21.16	39	19133	14806	34922953
Arteriospasm coronary	29.42	21.16	20	19152	3362	34934397
Angle closure glaucoma	29.25	21.16	13	19159	944	34936815
Disseminated intravascular coagulation	27.94	21.16	46	19126	21770	34915989
Product use in unapproved indication	27.94	21.16	133	19039	117366	34820393
Nasopharyngitis	27.76	21.16	3	19169	69965	34867794
Ventricular tachycardia	27.48	21.16	51	19121	26528	34911231
Hypercapnia	27.48	21.16	21	19151	4234	34933525
Hyperthermia malignant	26.73	21.16	16	19156	2161	34935598
Coma scale abnormal	26.37	21.16	20	19152	3988	34933771
Laryngomalacia	26.29	21.16	9	19163	323	34937436
Blood pressure increased	25.98	21.16	8	19164	88094	34849665
Oliguria	25.42	21.16	27	19145	8353	34929406
Blood cholesterol increased	24.56	21.16	42	19130	20501	34917258
Cholangiolitis	24.51	21.16	5	19167	20	34937739
Drug abuse	24.27	21.16	12	19160	99084	34838675
Malignant neoplasm progression	24.21	21.16	9	19163	88037	34849722
Hypoaesthesia	23.47	21.16	3	19169	61441	34876318
Bacterial infection	23.24	21.16	37	19135	17026	34920733
Iron deficiency	23.17	21.16	21	19151	5360	34932399
Activated partial thromboplastin time prolonged	22.88	21.16	26	19146	8669	34929090
Abdominal discomfort	22.66	21.16	3	19169	59832	34877927
Abdominal pain upper	21.97	21.16	6	19166	71484	34866275
Symmetrical drug-related intertriginous and flexural exanthema	21.88	21.16	8	19164	349	34937410

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Multiple organ dysfunction syndrome	961.77	20.13	609	32925	119637	79591217
Drug ineffective	907.63	20.13	1615	31919	1079298	78631556
Cardiogenic shock	626.66	20.13	320	33214	41594	79669260
Septic shock	455.95	20.13	392	33142	122409	79588445
Appendicolith	406.09	20.13	148	33386	8403	79702451
Cardiac arrest	405.18	20.13	427	33107	171669	79539185
Shock	338.39	20.13	217	33317	43331	79667523
Metabolic acidosis	327.71	20.13	274	33260	82255	79628599
Hypotension	316.05	20.13	619	32915	439698	79271156
Ventricular fibrillation	314.16	20.13	185	33349	31741	79679113
Appendicitis	288.23	20.13	151	33383	20643	79690211
Fatigue	275.85	20.13	34	33500	929693	78781161
Sepsis	274.61	20.13	442	33092	268986	79441868
Acute kidney injury	265.88	20.13	637	32897	518767	79192087
Respiratory failure	234.23	20.13	332	33202	180579	79530275
Propofol infusion syndrome	232.18	20.13	68	33466	1915	79708939
Stress cardiomyopathy	219.92	20.13	103	33431	11063	79699791
Acute respiratory distress syndrome	203.75	20.13	160	33374	43907	79666947
Renal failure	203.58	20.13	329	33205	200639	79510215
Haemodynamic instability	198.43	20.13	111	33423	17271	79693583
Bradycardia	198.31	20.13	264	33270	135293	79575561
Off label use	196.56	20.13	826	32708	906389	78804465
Lactic acidosis	191.45	20.13	189	33345	70170	79640684
Headache	183.88	20.13	28	33506	653744	79057110
Myoglobin urine present	182.44	20.13	48	33486	899	79709955
Renal injury	182.16	20.13	104	33430	16823	79694031
Peripheral ischaemia	179.36	20.13	85	33449	9372	79701482
Blood phosphorus increased	178.06	20.13	87	33447	10260	79700594
Arthralgia	176.54	20.13	18	33516	571785	79139069
Intentional overdose	165.22	20.13	213	33321	105747	79605107
Electrocardiogram QRS complex prolonged	162.56	20.13	83	33451	10750	79700104
Ascites	155.65	20.13	175	33359	75387	79635467
Dry gangrene	147.67	20.13	41	33493	948	79709906
Fear	147.47	20.13	100	33434	21886	79688968
Coma	145.56	20.13	195	33339	100454	79610400
Diarrhoea	135.27	20.13	104	33430	880385	78830469
Fall	130.06	20.13	24	33510	487605	79223249
Drug ineffective for unapproved indication	125.37	20.13	130	33404	51108	79659746
Serotonin syndrome	124.38	20.13	122	33412	44905	79665949
Rhabdomyolysis	124.14	20.13	183	33351	102948	79607906
Pulseless electrical activity	123.57	20.13	76	33458	14084	79696770
Vasoplegia syndrome	119.07	20.13	48	33486	3582	79707272
Ventricular tachycardia	118.41	20.13	115	33419	41820	79669034
Dizziness	116.92	20.13	38	33496	526403	79184451
Pruritus	115.24	20.13	15	33519	394633	79316221
Pharyngeal haemorrhage	114.88	20.13	36	33498	1280	79709574
Toxic epidermal necrolysis	114.30	20.13	116	33418	44465	79666389
Weight decreased	112.62	20.13	10	33524	355188	79355666
Anhedonia	110.13	20.13	72	33462	14826	79696028
Pain in extremity	108.51	20.13	13	33521	364525	79346329
Electrocardiogram QT prolonged	105.34	20.13	158	33376	90228	79620626
Rash	102.58	20.13	58	33476	578300	79132554
Acidosis	96.18	20.13	74	33460	19688	79691166
Hyperlactacidaemia	96.13	20.13	47	33487	5548	79705306
Malaise	94.47	20.13	44	33490	489825	79221029
Renal impairment	94.02	20.13	206	33328	157577	79553277
Back pain	92.63	20.13	10	33524	304170	79406684
Toxic encephalopathy	91.25	20.13	58	33476	11382	79699472
Intestinal ischaemia	90.52	20.13	61	33473	13209	79697645
Weight increased	90.13	20.13	7	33527	277379	79433475
Coagulopathy	89.23	20.13	92	33442	35914	79674940
Abdominal distension	88.73	20.13	171	33363	119479	79591375
Disseminated intravascular coagulation	87.78	20.13	91	33443	35751	79675103
Extremity necrosis	87.42	20.13	37	33497	3124	79707730
Overdose	87.41	20.13	220	33314	183986	79526868
Unevaluable event	85.41	20.13	111	33423	55474	79655380
Tachycardia	85.07	20.13	213	33321	177555	79533299
Product dose omission issue	84.06	20.13	5	33529	247532	79463322
Nasopharyngitis	83.64	20.13	6	33528	253875	79456979
Circulatory collapse	82.28	20.13	90	33444	37578	79673276
Asthenia	81.51	20.13	58	33476	511631	79199223
Diabetes insipidus	81.11	20.13	41	33493	5196	79705658
Abdominal discomfort	76.95	20.13	8	33526	250719	79460135
Hyponatraemia	76.75	20.13	205	33329	177643	79533211
Compartment syndrome	76.42	20.13	39	33495	5043	79705811
Alopecia	74.70	20.13	6	33528	231349	79479505
Respiratory depression	74.68	20.13	74	33460	27556	79683298
Emotional distress	74.57	20.13	88	33446	39881	79670973
Injury	74.42	20.13	124	33410	77372	79633482
Toxicity to various agents	73.53	20.13	361	33173	421179	79289675
Drug reaction with eosinophilia and systemic symptoms	72.98	20.13	111	33423	64133	79646721
Amylase increased	72.82	20.13	50	33484	11159	79699695
Peripheral swelling	72.37	20.13	13	33521	269604	79441250
Anion gap	72.09	20.13	29	33505	2152	79708702
Decreased appetite	70.34	20.13	28	33506	342390	79368464
Troponin increased	70.32	20.13	61	33473	19194	79691660
Sinusitis	69.37	20.13	3	33531	195498	79515356
Dyspnoea	67.85	20.13	164	33370	856861	78853993
Pulmonary oedema	67.71	20.13	128	33406	88126	79622728
Heparin-induced thrombocytopenia	67.22	20.13	45	33489	9637	79701217
Electrocardiogram ST segment elevation	65.55	20.13	42	33492	8355	79702499
Myocardial calcification	64.68	20.13	12	33522	36	79710818
Hypersensitivity	63.52	20.13	16	33518	262223	79448631
Gait disturbance	62.70	20.13	7	33527	207499	79503355
Anuria	62.02	20.13	59	33475	20904	79689950
Hyperdynamic left ventricle	61.52	20.13	17	33517	386	79710468
Insomnia	61.26	20.13	14	33520	245156	79465698
Left ventricle outflow tract obstruction	61.10	20.13	17	33517	396	79710458
Stress	60.49	20.13	115	33419	79497	79631357
Cough	60.45	20.13	40	33494	366749	79344105
Oliguria	60.23	20.13	52	33482	16257	79694597
Myasthenia gravis	57.41	20.13	42	33492	10357	79700497
Blood pressure increased	57.13	20.13	10	33524	211350	79499504
Hypoaesthesia	56.93	20.13	5	33529	179347	79531507
Activated partial thromboplastin time prolonged	55.89	20.13	47	33487	14181	79696673
Wrong product administered	55.73	20.13	39	33495	8973	79701881
Musculoskeletal stiffness	55.22	20.13	5	33529	175003	79535851
Atrioventricular block first degree	54.80	20.13	44	33490	12447	79698407
Ventricular hypokinesia	54.70	20.13	39	33495	9240	79701614
Infusion related reaction	53.95	20.13	15	33519	230222	79480632
Cholestasis	53.56	20.13	86	33448	52023	79658831
Paraesthesia	53.13	20.13	6	33528	176317	79534537
Muscle spasms	52.51	20.13	6	33528	174724	79536130
General physical health deterioration	51.73	20.13	241	33293	274997	79435857
Abdominal pain upper	51.67	20.13	15	33519	223804	79487050
Blood uric acid increased	50.15	20.13	43	33491	13317	79697537
Ventricular arrhythmia	49.47	20.13	36	33498	8804	79702050
Cardiotoxicity	49.25	20.13	41	33493	12198	79698656
Hypoxia	48.60	20.13	123	33411	103120	79607734
Distributive shock	47.44	20.13	23	33511	2664	79708190
Pulse absent	47.35	20.13	37	33497	10066	79700788
Nausea	46.54	20.13	226	33308	956970	78753884
Leukocytosis	46.42	20.13	73	33461	43382	79667472
Arteriospasm coronary	46.11	20.13	31	33503	6685	79704169
Brain death	45.82	20.13	29	33505	5648	79705206
Pain	45.72	20.13	148	33386	703654	79007200
Condition aggravated	45.49	20.13	363	33171	500761	79210093
Cardiovascular insufficiency	45.18	20.13	23	33511	2958	79707896
Hyperphosphataemia	45.14	20.13	30	33504	6346	79704508
Therapeutic product effect decreased	43.74	20.13	8	33526	163855	79546999
Alanine aminotransferase increased	43.69	20.13	159	33375	162411	79548443
Hyperkalaemia	43.52	20.13	126	33408	114272	79596582
Anion gap increased	43.11	20.13	24	33510	3696	79707158
Systolic dysfunction	42.66	20.13	24	33510	3771	79707083
Blood pressure decreased	42.21	20.13	114	33420	99352	79611502
Stomatitis	41.78	20.13	6	33528	146751	79564103
COVID-19 treatment	41.62	20.13	13	33521	457	79710397
Hepatic failure	41.14	20.13	84	33450	61128	79649726
Ischaemic hepatitis	40.72	20.13	23	33511	3641	79707213
Drug intolerance	40.60	20.13	31	33503	264088	79446766
Bronchitis	40.50	20.13	4	33530	130640	79580214
Injection site pain	40.18	20.13	4	33530	129834	79581020
Blood creatine phosphokinase increased	40.13	20.13	87	33447	66003	79644851
Urticaria	39.92	20.13	14	33520	185187	79525667
Drug therapy	39.80	20.13	16	33518	1185	79709669
Inappropriate schedule of product administration	39.14	20.13	5	33529	133623	79577231
Acute generalised exanthematous pustulosis	39.02	20.13	42	33492	17212	79693642
Analgesic therapy	38.91	20.13	15	33519	994	79709860
Acute lung injury	38.68	20.13	21	33513	3079	79707775
Muscular weakness	38.53	20.13	10	33524	160719	79550135
Torsade de pointes	38.49	20.13	44	33490	19268	79691586
Contusion	38.15	20.13	8	33526	148768	79562086
Hypertransaminasaemia	38.04	20.13	35	33499	11889	79698965
Blood lactate dehydrogenase increased	38.02	20.13	63	33471	39107	79671747
Cardio-respiratory arrest	37.93	20.13	116	33418	108394	79602460
Respiratory gas exchange disorder	37.69	20.13	14	33520	837	79710017
Confusional state	37.69	20.13	47	33487	317950	79392904
Chest pain	37.52	20.13	38	33496	282266	79428588
Mobility decreased	37.20	20.13	4	33530	122171	79588683
Dehydration	37.05	20.13	30	33504	248157	79462697
Renal tubular necrosis	36.90	20.13	49	33485	24990	79685864
Completed suicide	36.32	20.13	30	33504	245737	79465117
Reversible cerebral vasoconstriction syndrome	36.18	20.13	20	33514	3037	79707817
Acid base balance abnormal	35.94	20.13	11	33523	361	79710493
Neuropathy peripheral	35.42	20.13	8	33526	141297	79569557
Thrombocytopenia	35.19	20.13	211	33323	265048	79445806
Sleep disorder therapy	35.18	20.13	14	33520	1010	79709844
Burkholderia test positive	34.90	20.13	12	33522	573	79710281
Coma scale abnormal	34.77	20.13	29	33505	8649	79702205
Premature delivery	34.70	20.13	46	33488	23421	79687433
Electrocardiogram ST segment depression	34.65	20.13	23	33511	4855	79705999
Erythema	34.58	20.13	26	33508	223264	79487590
Cardiomyopathy	34.49	20.13	51	33483	28723	79682131
Ischaemia	34.48	20.13	28	33506	8047	79702807
Mydriasis	33.15	20.13	39	33495	17604	79693250
Blood potassium increased	32.41	20.13	50	33484	29225	79681629
Oropharyngeal pain	32.24	20.13	4	33530	109349	79601505
Loss of personal independence in daily activities	32.16	20.13	3	33531	102577	79608277
Contraindicated product administered	32.12	20.13	13	33521	157525	79553329
Infection	31.59	20.13	33	33501	241679	79469175
Nervous system disorder	31.33	20.13	47	33487	26809	79684045
Asthma	31.26	20.13	9	33525	135086	79575768
Influenza	31.18	20.13	8	33526	129598	79581256
Lower respiratory tract infection	31.05	20.13	8	33526	129212	79581642
Myalgia	30.88	20.13	20	33514	185621	79525233
Memory impairment	30.81	20.13	5	33529	111729	79599125
Diabetic macroangiopathy	30.70	20.13	8	33526	144	79710710
Palpitations	30.11	20.13	8	33526	126602	79584252
Vasoconstriction	28.68	20.13	11	33523	719	79710135
Unmasking of previously unidentified disease	28.66	20.13	15	33519	2042	79708812
Gastrointestinal disorder	28.54	20.13	8	33526	122197	79588657
Herpes zoster	28.46	20.13	3	33531	93080	79617774
Balance disorder	28.23	20.13	4	33530	98853	79612001
Suicide attempt	27.45	20.13	87	33447	82845	79628009
Depressed level of consciousness	27.20	20.13	96	33438	96556	79614298
Urinary tract infection	27.19	20.13	46	33488	274466	79436388
Chest discomfort	27.17	20.13	12	33522	138032	79572822
Mean arterial pressure increased	27.16	20.13	6	33528	51	79710803
Respiratory distress	26.92	20.13	69	33465	58270	79652584
Immune effector cell-associated neurotoxicity syndrome	26.50	20.13	21	33513	5827	79705027
Brain oedema	26.37	20.13	42	33492	25221	79685633
Systemic lupus erythematosus	26.37	20.13	9	33525	121140	79589714
Hyperthermia malignant	26.32	20.13	16	33518	2901	79707953
Acute respiratory failure	26.01	20.13	69	33465	59472	79651382
Incorrect route of product administration	25.96	20.13	50	33484	34879	79675975
Product use in unapproved indication	25.81	20.13	187	33347	250172	79460682
Vasodilatation	25.00	20.13	16	33518	3175	79707679
Cholangiolitis	24.92	20.13	5	33529	25	79710829
Respiratory acidosis	24.86	20.13	27	33507	11173	79699681
Catheter site haemorrhage	24.54	20.13	19	33515	5098	79705756
White blood cell count decreased	24.27	20.13	26	33508	188262	79522592
Gangrene	24.20	20.13	24	33510	8940	79701914
Pneumonia acinetobacter	24.14	20.13	7	33527	190	79710664
Pyrexia	24.02	20.13	177	33357	678532	79032322
Myocardial stunning	23.87	20.13	7	33527	198	79710656
Blood creatinine increased	23.60	20.13	128	33406	154929	79555925
Electrocardiogram P wave abnormal	23.55	20.13	8	33526	368	79710486
Oedema peripheral	23.42	20.13	44	33490	252244	79458610
Procedural hypotension	23.30	20.13	13	33521	2010	79708844
Hyperthermia	23.12	20.13	33	33501	18004	79692850
Hypoxic-ischaemic encephalopathy	23.11	20.13	22	33512	7798	79703056
Necrosis	23.05	20.13	24	33510	9469	79701385
Drug abuse	22.65	20.13	21	33513	162670	79548184
Product contamination microbial	22.64	20.13	10	33524	936	79709918
Hypercapnia	22.43	20.13	23	33511	8912	79701942
Pseudomonas infection	22.16	20.13	35	33499	20868	79689986
Malignant neoplasm progression	22.14	20.13	15	33519	135975	79574879
Impaired healing	21.89	20.13	5	33529	87650	79623204
Encephalopathy	21.66	20.13	70	33464	67327	79643527
Local anaesthetic systemic toxicity	21.61	20.13	10	33524	1044	79709810
Systolic anterior motion of mitral valve	21.56	20.13	5	33529	54	79710800
Therapy non-responder	21.26	20.13	86	33448	92219	79618635
Central nervous system injury	20.90	20.13	6	33528	157	79710697
Hospitalisation	20.51	20.13	7	33527	94229	79616625
Vitamin B1 decreased	20.40	20.13	8	33526	555	79710299
Influenza like illness	20.24	20.13	3	33531	71704	79639150
Human herpesvirus 6 infection reactivation	20.24	20.13	8	33526	567	79710287
Flushing	20.20	20.13	6	33528	88262	79622592

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	C01CA03	CARDIOVASCULAR SYSTEM CARDIAC THERAPY CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES Adrenergic and dopaminergic agents
FDA CS	M0003647	Catecholamines
FDA EPC	N0000175570	Catecholamine
MeSH PA	D018663	Adrenergic Agents
MeSH PA	D000322	Adrenergic Agonists
MeSH PA	D000316	Adrenergic alpha-Agonists
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018373	Peripheral Nervous System Agents
MeSH PA	D013566	Sympathomimetics
MeSH PA	D014662	Vasoconstrictor Agents
CHEBI has role	CHEBI:25512	neurotransmitters
CHEBI has role	CHEBI:35524	sympathomimetic
CHEBI has role	CHEBI:35569	alpha-adrenergic agonists
CHEBI has role	CHEBI:75771	Mus musculus metabolites
CHEBI has role	CHEBI:76967	human xenobiotic metabolites

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Bronchiectasis	indication	12295008	DOID:9563
Bronchitis	indication	32398004	DOID:6132
Low blood pressure	indication	45007003
Pulmonary emphysema	indication	87433001
Asthma	indication	195967001	DOID:2841
Asthma management	indication	406162001
Acute exacerbation of asthma	indication	708038006
Hypovolemia	contraindication	28560003
Hypercapnia	contraindication	29596007
Hypertensive disorder	contraindication	38341003	DOID:10763
Hypoxia	contraindication	389086002
Thrombosis	contraindication	439127006
Occlusive Vascular Disease	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.41	acidic
pKa2	12.03	acidic
pKa3	12.63	acidic
pKa4	8.83	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
EQ 16MG BASE/250ML (EQ 64MCG BASE/ML)	NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE	LONG GROVE PHARMS	N214628	Oct. 6, 2022	DISCN	SOLUTION	INTRAVENOUS	10226436	Jan. 30, 2038	INDICATED TO RAISE BLOOD PRESSURE IN ADULT PATIENTS WITH SEVERE, ACUTE HYPOTENSION
EQ 16MG BASE/250ML (EQ 64MCG BASE/ML)	NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE	LONG GROVE PHARMS	N214628	Oct. 6, 2022	DISCN	SOLUTION	INTRAVENOUS	10420735	Jan. 30, 2038	INDICATED TO RAISE BLOOD PRESSURE IN ADULT PATIENTS WITH SEVERE, ACUTE HYPOTENSION
EQ 16MG BASE/250ML (EQ 64MCG BASE/ML)	NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE	LONG GROVE PHARMS	N214628	Oct. 6, 2022	DISCN	SOLUTION	INTRAVENOUS	11413259	Jan. 30, 2038	INDICATED TO RAISE BLOOD PRESSURE IN ADULT PATIENTS WITH SEVERE, ACUTE HYPOTENSION
EQ 4MG BASE/250 ML (EQ 16MCG BASE/ML)	NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE	LONG GROVE PHARMS	N214628	Oct. 6, 2022	DISCN	SOLUTION	INTRAVENOUS	10226436	Jan. 30, 2038	INDICATED TO RAISE BLOOD PRESSURE IN ADULT PATIENTS WITH SEVERE, ACUTE HYPOTENSION
EQ 4MG BASE/250 ML (EQ 16MCG BASE/ML)	NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE	LONG GROVE PHARMS	N214628	Oct. 6, 2022	DISCN	SOLUTION	INTRAVENOUS	10420735	Jan. 30, 2038	INDICATED TO RAISE BLOOD PRESSURE IN ADULT PATIENTS WITH SEVERE, ACUTE HYPOTENSION
EQ 4MG BASE/250 ML (EQ 16MCG BASE/ML)	NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE	LONG GROVE PHARMS	N214628	Oct. 6, 2022	DISCN	SOLUTION	INTRAVENOUS	11413259	Jan. 30, 2038	INDICATED TO RAISE BLOOD PRESSURE IN ADULT PATIENTS WITH SEVERE, ACUTE HYPOTENSION
EQ 8MG BASE/250ML (EQ 32MCG BASE/ML)	NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE	LONG GROVE PHARMS	N214628	Oct. 6, 2022	DISCN	SOLUTION	INTRAVENOUS	10226436	Jan. 30, 2038	INDICATED TO RAISE BLOOD PRESSURE IN ADULT PATIENTS WITH SEVERE, ACUTE HYPOTENSION
EQ 8MG BASE/250ML (EQ 32MCG BASE/ML)	NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE	LONG GROVE PHARMS	N214628	Oct. 6, 2022	DISCN	SOLUTION	INTRAVENOUS	10420735	Jan. 30, 2038	INDICATED TO RAISE BLOOD PRESSURE IN ADULT PATIENTS WITH SEVERE, ACUTE HYPOTENSION
EQ 8MG BASE/250ML (EQ 32MCG BASE/ML)	NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE	LONG GROVE PHARMS	N214628	Oct. 6, 2022	DISCN	SOLUTION	INTRAVENOUS	11413259	Jan. 30, 2038	INDICATED TO RAISE BLOOD PRESSURE IN ADULT PATIENTS WITH SEVERE, ACUTE HYPOTENSION

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Alpha-2C adrenergic receptor	GPCR	P18825	ADA2C_HUMAN	AGONIST	Ki	7.20	CHEMBL	CHEMBL
Alpha-1A adrenergic receptor	GPCR	P35348	ADA1A_HUMAN	AGONIST	Ki	5.82	CHEMBL	CHEMBL
Alpha-1D adrenergic receptor	GPCR	P25100	ADA1D_HUMAN	AGONIST	Ki	7.40	IUPHAR	CHEMBL
Alpha-1B adrenergic receptor	GPCR	P35368	ADA1B_HUMAN	AGONIST	Ki	4.69	CHEMBL	CHEMBL
Beta-2 adrenergic receptor	GPCR	P07550	ADRB2_HUMAN	AGONIST	Kd	5.40	CHEMBL	CHEMBL
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN	AGONIST	Ki	7.18	CHEMBL	CHEMBL
Beta-1 adrenergic receptor	GPCR	P08588	ADRB1_HUMAN	AGONIST	Ki	6	IUPHAR	CHEMBL
D(1A) dopamine receptor	GPCR	P21728	DRD1_HUMAN		Kd	4.30	CHEMBL
D(2) dopamine receptor	GPCR	P14416	DRD2_HUMAN		Ki	5.89	CHEMBL
Alpha-2B adrenergic receptor	GPCR	P18089	ADA2B_HUMAN		Ki	6.48	PDSP
Beta-3 adrenergic receptor	GPCR	P13945	ADRB3_HUMAN		Ki	5.37	PDSP
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN		Ki	5.07	PDSP
Mu-type opioid receptor	GPCR		OPRM_RAT		Ki	4.85	CHEMBL
Beta-2 adrenergic receptor	GPCR		ADRB2_BOVIN		Ki	5.22	CHEMBL
Beta-1 adrenergic receptor	GPCR		ADRB1_RAT		Ki	6.90	CHEMBL
Beta-2 adrenergic receptor	GPCR		ADRB2_CANFA		Ki	5.30	CHEMBL
Alpha-1A adrenergic receptor	GPCR		ADA1A_BOVIN		Ki	6.35	CHEMBL
Beta-2 adrenergic receptor	GPCR		ADRB2_RAT		Ki	5.38	CHEMBL
Alpha-1B adrenergic receptor	GPCR		ADA1B_MESAU		Ki	6.58	CHEMBL
Beta-1 adrenergic receptor	GPCR		B0FL73_CAVPO		Ki	6.40	CHEMBL
Adrenergic receptor alpha-2	GPCR		ADA2B_RAT ADA2C_RAT ADA2A_RAT		Ki	8.32	CHEMBL
Adrenergic receptor alpha-1	GPCR		ADA1B_RAT ADA1D_RAT ADA1A_RAT		Ki	6.41	CHEMBL
Adrenergic receptor alpha	GPCR		ADA1B_RAT ADA2B_RAT ADA2C_RAT ADA2A_RAT ADA1D_RAT ADA1A_RAT		IC50	7.80	CHEMBL
Adrenergic receptor beta	GPCR		ADRB2_RAT ADRB1_RAT ADRB3_RAT		IC50	6	CHEMBL
Alpha-2C adrenergic receptor	GPCR		ADA2C_MOUSE		Ki	6.19	CHEMBL
Alpha-2A adrenergic receptor	GPCR		ADA2A_MOUSE		Ki	5.24	CHEMBL
Alpha-2B adrenergic receptor	GPCR		ADA2B_RAT		Ki	7.11	CHEMBL

External reference:

ID	Source
4019859	VUID
N0000147945	NUI
D00076	KEGG_DRUG
108341-18-0	SECONDARY_CAS_RN
4018242	VANDF
4019859	VANDF
C0028351	UMLSCUI
CHEBI:33569	CHEBI
LT4	PDB_CHEM_ID
CHEMBL1434513	ChEMBL_ID
CHEMBL1437	ChEMBL_ID
DB00368	DRUGBANK_ID
CHEMBL1356607	ChEMBL_ID
D009638	MESH_DESCRIPTOR_UI
439260	PUBCHEM_CID
33	INN_ID
484	IUPHAR_LIGAND_ID
X4W3ENH1CV	UNII
7508	RXNORM
2706	MMSL
333906	MMSL
35060	MMSL
5186	MMSL
NOCODE	MMSL
d00323	MMSL
001777	NDDF
004718	NDDF
111130009	SNOMEDCT_US
45555007	SNOMEDCT_US
77673009	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Norepinephrine Bitartrate	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9318	INJECTION	1 mg	INTRAVENOUS	ANDA	24 sections
NOREPINEPHRINE BITARTRATE	HUMAN PRESCRIPTION DRUG LABEL	1	0338-0108	INJECTION, SOLUTION	8 mg	INTRAVENOUS	NDA	24 sections
NOREPINEPHRINE BITARTRATE	HUMAN PRESCRIPTION DRUG LABEL	1	0338-0108	INJECTION, SOLUTION	8 mg	INTRAVENOUS	NDA	24 sections
NOREPINEPHRINE BITARTRATE	HUMAN PRESCRIPTION DRUG LABEL	1	0338-0108	INJECTION, SOLUTION	8 mg	INTRAVENOUS	NDA	24 sections
NOREPINEPHRINE BITARTRATE	HUMAN PRESCRIPTION DRUG LABEL	1	0338-0108	INJECTION, SOLUTION	8 mg	INTRAVENOUS	NDA	24 sections
NOREPINEPHRINE BITARTRATE	HUMAN PRESCRIPTION DRUG LABEL	1	0338-0112	INJECTION, SOLUTION	4 mg	INTRAVENOUS	NDA	24 sections
NOREPINEPHRINE BITARTRATE	HUMAN PRESCRIPTION DRUG LABEL	1	0338-0112	INJECTION, SOLUTION	4 mg	INTRAVENOUS	NDA	24 sections
NOREPINEPHRINE BITARTRATE	HUMAN PRESCRIPTION DRUG LABEL	1	0338-0112	INJECTION, SOLUTION	4 mg	INTRAVENOUS	NDA	24 sections
NOREPINEPHRINE BITARTRATE	HUMAN PRESCRIPTION DRUG LABEL	1	0338-0112	INJECTION, SOLUTION	4 mg	INTRAVENOUS	NDA	24 sections
Levophed	HUMAN PRESCRIPTION DRUG LABEL	1	0409-1443	INJECTION, SOLUTION, CONCENTRATE	1 mg	INTRAVENOUS	NDA	20 sections
Levophed	HUMAN PRESCRIPTION DRUG LABEL	1	0409-1443	INJECTION, SOLUTION, CONCENTRATE	1 mg	INTRAVENOUS	NDA	20 sections
LEVOPHED	Human prescription drug label	1	0409-3375	INJECTION, SOLUTION, CONCENTRATE	1 mg	INTRAVENOUS	NDA	27 sections
LEVOPHED	Human prescription drug label	1	0409-3375	INJECTION, SOLUTION, CONCENTRATE	1 mg	INTRAVENOUS	NDA	27 sections
Norepinephrine Bitartrate	HUMAN PRESCRIPTION DRUG LABEL	1	0703-1153	INJECTION, SOLUTION, CONCENTRATE	1 mg	INTRAVENOUS	ANDA	24 sections
Norepinephrine Bitartrate	HUMAN PRESCRIPTION DRUG LABEL	1	0703-1153	INJECTION, SOLUTION, CONCENTRATE	1 mg	INTRAVENOUS	ANDA	24 sections
NOREPINEPHRINE BITARTRATE	HUMAN PRESCRIPTION DRUG LABEL	1	0781-3755	INJECTION, SOLUTION, CONCENTRATE	1 mg	INTRAVENOUS	ANDA	24 sections
NOREPINEPHRINE BITARTRATE	HUMAN PRESCRIPTION DRUG LABEL	1	0781-3755	INJECTION, SOLUTION, CONCENTRATE	1 mg	INTRAVENOUS	ANDA	24 sections
NOREPINEPHRINE BITARTRATE	HUMAN PRESCRIPTION DRUG LABEL	1	0781-3755	INJECTION, SOLUTION, CONCENTRATE	1 mg	INTRAVENOUS	ANDA	24 sections
Norepinephrine Bitartrate	HUMAN PRESCRIPTION DRUG LABEL	1	25021-316	INJECTION, SOLUTION	1 mg	INTRAVENOUS	ANDA	25 sections
Norepinephrine bitartrate	HUMAN PRESCRIPTION DRUG LABEL	1	36000-162	INJECTION	1 mg	INTRAVENOUS	ANDA	18 sections
Norepinephrine bitartrate	HUMAN PRESCRIPTION DRUG LABEL	1	36000-162	INJECTION	1 mg	INTRAVENOUS	ANDA	18 sections
NOREPINEPHRINE BITARTRATE	HUMAN PRESCRIPTION DRUG LABEL	1	42023-245	INJECTION, SOLUTION	4 mg	INTRAVENOUS	NDA	21 sections
NOREPINEPHRINE BITARTRATE	HUMAN PRESCRIPTION DRUG LABEL	1	42023-246	INJECTION, SOLUTION	8 mg	INTRAVENOUS	NDA	21 sections
NOREPINEPHRINE BITARTRATE	HUMAN PRESCRIPTION DRUG LABEL	1	42023-247	INJECTION, SOLUTION	16 mg	INTRAVENOUS	NDA	21 sections
Norepinephrine Bitartrate	HUMAN PRESCRIPTION DRUG LABEL	1	43066-997	INJECTION	1 mg	INTRAVENOUS	ANDA	24 sections
NOREPINEPHRINE BITARTRATE	HUMAN PRESCRIPTION DRUG LABEL	1	44567-640	INJECTION, SOLUTION, CONCENTRATE	0.02 mg	INTRAVENOUS	NDA	24 sections
NOREPINEPHRINE BITARTRATE	HUMAN PRESCRIPTION DRUG LABEL	1	44567-640	INJECTION, SOLUTION, CONCENTRATE	0.02 mg	INTRAVENOUS	NDA	24 sections
NOREPINEPHRINE BITARTRATE	HUMAN PRESCRIPTION DRUG LABEL	1	44567-641	INJECTION, SOLUTION, CONCENTRATE	0.03 mg	INTRAVENOUS	NDA	24 sections
NOREPINEPHRINE BITARTRATE	HUMAN PRESCRIPTION DRUG LABEL	1	44567-641	INJECTION, SOLUTION, CONCENTRATE	0.03 mg	INTRAVENOUS	NDA	24 sections
NOREPINEPHRINE BITARTRATE	HUMAN PRESCRIPTION DRUG LABEL	1	44567-642	INJECTION, SOLUTION, CONCENTRATE	0.06 mg	INTRAVENOUS	NDA	24 sections